NEWS
-
PRESS RELEASE
Metcela Inc. Completes the Series C Financing of Total $14 Million
Total of $14 million (1.87 billion JPY) was raised in the Series C round, and cumulative $35 million (4.6 billion JPY, including grants) has been raised to date. Metcela is aiming to create new therapeutic options for heart failure by establishing an ecosystem for autologous cell therapy.
-
PRESS RELEASE
Metcela Acquires Japan Regenerative Medicine Co., Ltd., Developing Cardiac Stem Cell-based Therapy
Through this acquisition, Metcela will add an autologous cell product for pediatric congenital heart disease to its pipeline and significantly strengthen its clinical development infrastructure for regenerative medicine products.
-
PRESS RELEASE
Metcela Raises Funds from Two University Venture Capitals
Metcela intends to significantly strengthen its collaboration with Osaka University and Tohoku University in its future development activities through this financing.
-
NEWS
Iwamiya, Metcela’s co-CEO, spoke at ACCJ x LINK-J event: “The Front Line of the Regenerative Medicine Business: Practical Application of Cell Medicine”
One of our Co-CEO, Iwamiya, spoke at an event hosted by The American Chamber of Commerce in Japan (ACCJ) and supported by the Life Science Innovation Network Japan (LINK-J).
